Social Health: The Future of Healthcare Marketing
Newsletters and Deep Dive digital magazine
With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers.
As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself in a unique position to reimagine traditional direct-to-consumer (DTC) efforts and peer-to-peer communication. That means going beyond TV ad celebrities or one-off Instagram relationships limited to short-term PR value.
When it comes to motivating consumers to take action with their health, and especially inspiring people to speak to a doctor, pharma needs to be thinking about new ways not just to reach patients but to activate them.
Social health—the digital means by which health consumers engage with each other and their health—has broad applications for the healthcare industry overall. To learn more, read the full article on health-union.com.
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
A report has concluded that the current regulatory framework in the UK is inadequate for healthcare AI, and makes 44 recommendations to set it right.
A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.
Read Medidata’s 2nd annual survey, 'The State of AI in Clinical Trials. From Pilot to Practice: Insights into AI Adoption, Impact, and Expectations'.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines.
A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflam
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development
Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox